01—Abstract
Summary
Summary of the 10-K filed February 19, 2021. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc.'s 2020 10-K filing highlights a transformative year, largely defined by the significant acquisition of Allergan plc.
This strategic move has broadened AbbVie's therapeutic reach into aesthetics, neuroscience, and eye care, creating a more diversified business portfolio. The company reported robust net revenues of $45.8 billiona, a substantial increase driven by the Allergan integration, as well as growth in key immunology products like Skyrizi and Rinvoq, and continued strength in oncology with Imbruvica and Venclexta. Despite the positive revenue growth, the company navigated challenges including the impact of the COVID-19 pandemic, which led to lower new patient starts across its portfolio.
Looking ahead, AbbVie's strategic objectives focus on maximizing the benefits of the Allergan acquisition, driving revenue growth through commercial execution and pipeline expansion, optimizing operations, and returning value to shareholders. The company remains committed to innovation, with over 90 compounds in development, and is well-positioned to leverage its expanded portfolio and infrastructure for sustained long-term growth. Investors should closely monitor AbbVie's ability to integrate Allergan successfully, manage the ongoing impact of COVID-19, and navigate patent expirations, particularly for Humira, while capitalizing on its new growth drivers.
02—Key points
Key Highlights
- AbbVie completed the transformative acquisition of Allergan plc on May 8, 2020, significantly expanding its portfolio into aesthetics, neuroscience, and eye care.
- AbbVie reported a 37.7% increase in net revenues to $45.8 billion in 2020, driven by the Allergan acquisition and growth in key products like Skyrizi and Rinvoq.
- Humira sales showed resilience, particularly in the U.S., though international sales were impacted by biosimilar competition; U.S. Humira patent protection is expected to remain until 2023.
- The company continues to invest heavily in R&D, with over 90 compounds in development, including significant advancements in immunology and oncology.
- AbbVie experienced the impact of COVID-19, leading to lower new patient starts, though the overall impact on operations was managed.
- The company declared a quarterly cash dividend of $1.30 per share, reflecting a 10.2% increase, demonstrating a commitment to returning value to shareholders.
- Integration of Allergan is expected to yield over $2 billion in annual cost synergies, with significant charges anticipated through 2022 to achieve these efficiencies.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, AbbVie Inc. kept $0.10.
- Revenue$45.80B100.0%
- Cost of revenue−$15.39B33.6%
- Gross profit$30.42B66.4%
- Operating costs−$19.05B41.6%
- Operating income$11.36B24.8%
- Interest, other & tax−$6.75B14.7%
- Net income$4.62B10.1%
Where FY2020 revenue went
$45.80B- Cost of revenue: $15.39B, 34% of revenue
- SG&A: $11.30B, 25% of revenue
- Other operating costs: $7.75B, 17% of revenue
- Interest, other & tax: $6.75B, 15% of revenue
- Net income: $4.62B, 10% of revenue
Kept 10% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 19, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $45.80B$33.27B | +37.7% |
| Cost of Revenue | $15.39B$7.44B | +106.8% |
| Gross Profit | $30.42B$25.83B | +17.8% |
| SG&A Expenses | $11.30B$6.94B | +62.8% |
| Operating Expenses | $34.44B$20.28B | +69.8% |
| Operating Income | $11.36B$12.98B | −12.5% |
| Interest Expense | $2.45B$1.78B | +37.6% |
| Net Income | $4.62B$7.88B | −41.4% |
| EPS (Basic) | $2.73$5.30 | −48.5% |
| EPS (Diluted) | $2.72$5.28 | −48.5% |
| Shares Outstanding (Basic) | 1.67B1.48B | +12.6% |
| Shares Outstanding (Diluted) | 1.67B1.48B | +12.7% |
05—Questions
Frequently Asked Questions
What was the main strategic event for AbbVie in 2020?
The most significant event for AbbVie in 2020 was the completion of its acquisition of Allergan plc on May 8, 2020. This acquisition substantially diversified AbbVie's product portfolio and expanded its presence in key therapeutic areas such as aesthetics, neuroscience, and eye care.
How did the Allergan acquisition impact AbbVie's financial performance?
The acquisition of Allergan significantly boosted AbbVie's net revenues by $10.3 billion in 2020, contributing to an overall revenue increase of 37.7% to $45.8 billion. While this growth is substantial, the integration also incurred significant acquisition and integration expenses, impacting earnings per share.
What are AbbVie's key growth drivers following the Allergan acquisition?
AbbVie's key growth drivers include continued expansion of its immunology portfolio with Skyrizi and Rinvoq, strong performance in hematologic oncology with Imbruvica and Venclexta, and the integration and commercialization of Allergan's aesthetics and neuroscience products. The company aims to leverage its expanded commercial strength and international infrastructure across these areas.
What are the primary risks facing AbbVie as outlined in the filing?
Key risks highlighted include the expiration or loss of patent protection for its products, particularly Humira, which could lead to increased competition from generics and biosimilars. Other significant risks include the ongoing impact of the COVID-19 pandemic on operations and patient access, potential challenges in research and development, competition from other pharmaceutical companies, and the successful integration of the Allergan acquisition.
06—Continue